Predictive markers for anti-PD-1/PD-L1 therapy in non-small cell lung cancer—where are we? Article Swipe
Matthew Evans
,
Brendan O’Sullivan
,
Matthew R. Smith
,
Philippe Tanière
·
YOU?
·
· 2018
· Open Access
·
· DOI: https://doi.org/10.21037/tlcr.2018.06.09
YOU?
·
· 2018
· Open Access
·
· DOI: https://doi.org/10.21037/tlcr.2018.06.09
The selection of patients for immunotherapy remains challenging given the lack of highly specific and highly sensitive biomarkers. Nevertheless, it is essential that testing laboratories are able to fulfil licencing criteria by providing the tests which have been validated as providing useful predictive information. Programmed cell death protein 1 (PD-1) expression assessment is now established in routine practice, although the situation regarding the selection of a particular assay remains complex, and testing protocols are likely to change in future. It is probable that programmed death-ligand 1 (PD-L1) expression assessment will be supplemented in the near future by tumour mutation burden (TMB), but this will require novel solutions to allow testing to be completed using small tissue samples and within narrow timeframes. While DNA mismatch repair (MMR) testing and CD8 T-cell density may also have a role to play in predicting immunotherapy response, their roles are not well-defined at present. Above all, the main challenge facing laboratories will be to perform this multitude of tests alongside the molecular markers already established in clinical practice [e.g., epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) translocation, ROS proto-oncogene 1 (ROS1) translocation]; the challenge for pathologists and clinicians will be to develop algorithms which will integrate the complex set of results from these tests and provide clinically-useful management regimens.
Related Topics
Concepts
Metadata
- Type
- review
- Language
- en
- Landing Page
- https://doi.org/10.21037/tlcr.2018.06.09
- https://tlcr.amegroups.com/article/viewFile/22942/17376
- OA Status
- hybrid
- Cited By
- 33
- References
- 44
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W2890556078
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W2890556078Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.21037/tlcr.2018.06.09Digital Object Identifier
- Title
-
Predictive markers for anti-PD-1/PD-L1 therapy in non-small cell lung cancer—where are we?Work title
- Type
-
reviewOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2018Year of publication
- Publication date
-
2018-11-14Full publication date if available
- Authors
-
Matthew Evans, Brendan O’Sullivan, Matthew R. Smith, Philippe TanièreList of authors in order
- Landing page
-
https://doi.org/10.21037/tlcr.2018.06.09Publisher landing page
- PDF URL
-
https://tlcr.amegroups.com/article/viewFile/22942/17376Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
hybridOpen access status per OpenAlex
- OA URL
-
https://tlcr.amegroups.com/article/viewFile/22942/17376Direct OA link when available
- Concepts
-
Medicine, Immunotherapy, Anaplastic lymphoma kinase, ROS1, Lung cancer, Cancer, Bioinformatics, CD8, Epidermal growth factor receptor, Cancer research, Computational biology, Oncology, Immunology, Internal medicine, Antigen, Biology, Adenocarcinoma, Malignant pleural effusionTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
33Total citation count in OpenAlex
- Citations by year (recent)
-
2024: 2, 2023: 5, 2022: 4, 2021: 6, 2020: 6Per-year citation counts (last 5 years)
- References (count)
-
44Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W2890556078 |
|---|---|
| doi | https://doi.org/10.21037/tlcr.2018.06.09 |
| ids.doi | https://doi.org/10.21037/tlcr.2018.06.09 |
| ids.mag | 2890556078 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/30505713 |
| ids.openalex | https://openalex.org/W2890556078 |
| fwci | 2.45213099 |
| type | review |
| title | Predictive markers for anti-PD-1/PD-L1 therapy in non-small cell lung cancer—where are we? |
| biblio.issue | 5 |
| biblio.volume | 7 |
| biblio.last_page | 690 |
| biblio.first_page | 682 |
| topics[0].id | https://openalex.org/T10158 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9998999834060669 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2730 |
| topics[0].subfield.display_name | Oncology |
| topics[0].display_name | Cancer Immunotherapy and Biomarkers |
| topics[1].id | https://openalex.org/T10417 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9988999962806702 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2740 |
| topics[1].subfield.display_name | Pulmonary and Respiratory Medicine |
| topics[1].display_name | Lung Cancer Treatments and Mutations |
| topics[2].id | https://openalex.org/T11287 |
| topics[2].field.id | https://openalex.org/fields/13 |
| topics[2].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[2].score | 0.9976999759674072 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1306 |
| topics[2].subfield.display_name | Cancer Research |
| topics[2].display_name | Cancer Genomics and Diagnostics |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.7132137417793274 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C2777701055 |
| concepts[1].level | 3 |
| concepts[1].score | 0.6132297515869141 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q1427096 |
| concepts[1].display_name | Immunotherapy |
| concepts[2].id | https://openalex.org/C117643217 |
| concepts[2].level | 4 |
| concepts[2].score | 0.6078861951828003 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q17824987 |
| concepts[2].display_name | Anaplastic lymphoma kinase |
| concepts[3].id | https://openalex.org/C2775999482 |
| concepts[3].level | 4 |
| concepts[3].score | 0.490892231464386 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q18031208 |
| concepts[3].display_name | ROS1 |
| concepts[4].id | https://openalex.org/C2776256026 |
| concepts[4].level | 2 |
| concepts[4].score | 0.46076157689094543 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q47912 |
| concepts[4].display_name | Lung cancer |
| concepts[5].id | https://openalex.org/C121608353 |
| concepts[5].level | 2 |
| concepts[5].score | 0.46019911766052246 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[5].display_name | Cancer |
| concepts[6].id | https://openalex.org/C60644358 |
| concepts[6].level | 1 |
| concepts[6].score | 0.44308921694755554 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q128570 |
| concepts[6].display_name | Bioinformatics |
| concepts[7].id | https://openalex.org/C167672396 |
| concepts[7].level | 3 |
| concepts[7].score | 0.43675294518470764 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q417800 |
| concepts[7].display_name | CD8 |
| concepts[8].id | https://openalex.org/C2779438470 |
| concepts[8].level | 3 |
| concepts[8].score | 0.4201701879501343 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q424401 |
| concepts[8].display_name | Epidermal growth factor receptor |
| concepts[9].id | https://openalex.org/C502942594 |
| concepts[9].level | 1 |
| concepts[9].score | 0.3915640711784363 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q3421914 |
| concepts[9].display_name | Cancer research |
| concepts[10].id | https://openalex.org/C70721500 |
| concepts[10].level | 1 |
| concepts[10].score | 0.3788335919380188 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q177005 |
| concepts[10].display_name | Computational biology |
| concepts[11].id | https://openalex.org/C143998085 |
| concepts[11].level | 1 |
| concepts[11].score | 0.3341193199157715 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[11].display_name | Oncology |
| concepts[12].id | https://openalex.org/C203014093 |
| concepts[12].level | 1 |
| concepts[12].score | 0.3002983331680298 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[12].display_name | Immunology |
| concepts[13].id | https://openalex.org/C126322002 |
| concepts[13].level | 1 |
| concepts[13].score | 0.2159508466720581 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[13].display_name | Internal medicine |
| concepts[14].id | https://openalex.org/C147483822 |
| concepts[14].level | 2 |
| concepts[14].score | 0.21386533975601196 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q103537 |
| concepts[14].display_name | Antigen |
| concepts[15].id | https://openalex.org/C86803240 |
| concepts[15].level | 0 |
| concepts[15].score | 0.16738790273666382 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[15].display_name | Biology |
| concepts[16].id | https://openalex.org/C2781182431 |
| concepts[16].level | 3 |
| concepts[16].score | 0.11609774827957153 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q356033 |
| concepts[16].display_name | Adenocarcinoma |
| concepts[17].id | https://openalex.org/C2776232967 |
| concepts[17].level | 3 |
| concepts[17].score | 0.0 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q6743514 |
| concepts[17].display_name | Malignant pleural effusion |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.7132137417793274 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/immunotherapy |
| keywords[1].score | 0.6132297515869141 |
| keywords[1].display_name | Immunotherapy |
| keywords[2].id | https://openalex.org/keywords/anaplastic-lymphoma-kinase |
| keywords[2].score | 0.6078861951828003 |
| keywords[2].display_name | Anaplastic lymphoma kinase |
| keywords[3].id | https://openalex.org/keywords/ros1 |
| keywords[3].score | 0.490892231464386 |
| keywords[3].display_name | ROS1 |
| keywords[4].id | https://openalex.org/keywords/lung-cancer |
| keywords[4].score | 0.46076157689094543 |
| keywords[4].display_name | Lung cancer |
| keywords[5].id | https://openalex.org/keywords/cancer |
| keywords[5].score | 0.46019911766052246 |
| keywords[5].display_name | Cancer |
| keywords[6].id | https://openalex.org/keywords/bioinformatics |
| keywords[6].score | 0.44308921694755554 |
| keywords[6].display_name | Bioinformatics |
| keywords[7].id | https://openalex.org/keywords/cd8 |
| keywords[7].score | 0.43675294518470764 |
| keywords[7].display_name | CD8 |
| keywords[8].id | https://openalex.org/keywords/epidermal-growth-factor-receptor |
| keywords[8].score | 0.4201701879501343 |
| keywords[8].display_name | Epidermal growth factor receptor |
| keywords[9].id | https://openalex.org/keywords/cancer-research |
| keywords[9].score | 0.3915640711784363 |
| keywords[9].display_name | Cancer research |
| keywords[10].id | https://openalex.org/keywords/computational-biology |
| keywords[10].score | 0.3788335919380188 |
| keywords[10].display_name | Computational biology |
| keywords[11].id | https://openalex.org/keywords/oncology |
| keywords[11].score | 0.3341193199157715 |
| keywords[11].display_name | Oncology |
| keywords[12].id | https://openalex.org/keywords/immunology |
| keywords[12].score | 0.3002983331680298 |
| keywords[12].display_name | Immunology |
| keywords[13].id | https://openalex.org/keywords/internal-medicine |
| keywords[13].score | 0.2159508466720581 |
| keywords[13].display_name | Internal medicine |
| keywords[14].id | https://openalex.org/keywords/antigen |
| keywords[14].score | 0.21386533975601196 |
| keywords[14].display_name | Antigen |
| keywords[15].id | https://openalex.org/keywords/biology |
| keywords[15].score | 0.16738790273666382 |
| keywords[15].display_name | Biology |
| keywords[16].id | https://openalex.org/keywords/adenocarcinoma |
| keywords[16].score | 0.11609774827957153 |
| keywords[16].display_name | Adenocarcinoma |
| language | en |
| locations[0].id | doi:10.21037/tlcr.2018.06.09 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S2764539079 |
| locations[0].source.issn | 2218-6751, 2226-4477 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 2218-6751 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Translational Lung Cancer Research |
| locations[0].source.host_organization | https://openalex.org/P4310321814 |
| locations[0].source.host_organization_name | AME Publishing Company |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310321814 |
| locations[0].license | cc-by-nc-nd |
| locations[0].pdf_url | https://tlcr.amegroups.com/article/viewFile/22942/17376 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by-nc-nd |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Translational Lung Cancer Research |
| locations[0].landing_page_url | https://doi.org/10.21037/tlcr.2018.06.09 |
| locations[1].id | pmid:30505713 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Translational lung cancer research |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/30505713 |
| locations[2].id | pmh:oai:pubmedcentral.nih.gov:6249622 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S2764455111 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed Central |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Transl Lung Cancer Res |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/6249622 |
| locations[3].id | pmh:oai:europepmc.org:5237898 |
| locations[3].is_oa | False |
| locations[3].source.id | https://openalex.org/S4306400806 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | Europe PMC (PubMed Central) |
| locations[3].source.host_organization | https://openalex.org/I1303153112 |
| locations[3].source.host_organization_name | European Bioinformatics Institute |
| locations[3].source.host_organization_lineage | https://openalex.org/I1303153112 |
| locations[3].license | |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | Text |
| locations[3].license_id | |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | |
| locations[3].landing_page_url | http://europepmc.org/pmc/articles/PMC6249622 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5063550488 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-2676-6130 |
| authorships[0].author.display_name | Matthew Evans |
| authorships[0].countries | GB |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I2799307867 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Cellular Pathology/Molecular Pathology, Queen Elizabeth Hospital Birmingham, Birmingham, UK |
| authorships[0].institutions[0].id | https://openalex.org/I2799307867 |
| authorships[0].institutions[0].ror | https://ror.org/048emj907 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I1308923049, https://openalex.org/I2799307867 |
| authorships[0].institutions[0].country_code | GB |
| authorships[0].institutions[0].display_name | Queen Elizabeth Hospital Birmingham |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Matthew Evans |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Department of Cellular Pathology/Molecular Pathology, Queen Elizabeth Hospital Birmingham, Birmingham, UK |
| authorships[1].author.id | https://openalex.org/A5063681577 |
| authorships[1].author.orcid | https://orcid.org/0000-0001-9773-2571 |
| authorships[1].author.display_name | Brendan O’Sullivan |
| authorships[1].countries | GB |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I2799307867 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Cellular Pathology/Molecular Pathology, Queen Elizabeth Hospital Birmingham, Birmingham, UK |
| authorships[1].institutions[0].id | https://openalex.org/I2799307867 |
| authorships[1].institutions[0].ror | https://ror.org/048emj907 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I1308923049, https://openalex.org/I2799307867 |
| authorships[1].institutions[0].country_code | GB |
| authorships[1].institutions[0].display_name | Queen Elizabeth Hospital Birmingham |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Brendan O’Sullivan |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Cellular Pathology/Molecular Pathology, Queen Elizabeth Hospital Birmingham, Birmingham, UK |
| authorships[2].author.id | https://openalex.org/A5101655026 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-5983-8989 |
| authorships[2].author.display_name | Matthew R. Smith |
| authorships[2].countries | GB |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I2799307867 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Cellular Pathology/Molecular Pathology, Queen Elizabeth Hospital Birmingham, Birmingham, UK |
| authorships[2].institutions[0].id | https://openalex.org/I2799307867 |
| authorships[2].institutions[0].ror | https://ror.org/048emj907 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I1308923049, https://openalex.org/I2799307867 |
| authorships[2].institutions[0].country_code | GB |
| authorships[2].institutions[0].display_name | Queen Elizabeth Hospital Birmingham |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Matthew Smith |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Cellular Pathology/Molecular Pathology, Queen Elizabeth Hospital Birmingham, Birmingham, UK |
| authorships[3].author.id | https://openalex.org/A5061777679 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-4638-4551 |
| authorships[3].author.display_name | Philippe Tanière |
| authorships[3].countries | GB |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I2799307867 |
| authorships[3].affiliations[0].raw_affiliation_string | Department of Cellular Pathology/Molecular Pathology, Queen Elizabeth Hospital Birmingham, Birmingham, UK |
| authorships[3].institutions[0].id | https://openalex.org/I2799307867 |
| authorships[3].institutions[0].ror | https://ror.org/048emj907 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I1308923049, https://openalex.org/I2799307867 |
| authorships[3].institutions[0].country_code | GB |
| authorships[3].institutions[0].display_name | Queen Elizabeth Hospital Birmingham |
| authorships[3].author_position | last |
| authorships[3].raw_author_name | Philippe Taniere |
| authorships[3].is_corresponding | True |
| authorships[3].raw_affiliation_strings | Department of Cellular Pathology/Molecular Pathology, Queen Elizabeth Hospital Birmingham, Birmingham, UK |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://tlcr.amegroups.com/article/viewFile/22942/17376 |
| open_access.oa_status | hybrid |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Predictive markers for anti-PD-1/PD-L1 therapy in non-small cell lung cancer—where are we? |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10158 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9998999834060669 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2730 |
| primary_topic.subfield.display_name | Oncology |
| primary_topic.display_name | Cancer Immunotherapy and Biomarkers |
| related_works | https://openalex.org/W2607398004, https://openalex.org/W4386241379, https://openalex.org/W2138715987, https://openalex.org/W1970822548, https://openalex.org/W2948378666, https://openalex.org/W2606295982, https://openalex.org/W2772410896, https://openalex.org/W2562692736, https://openalex.org/W2611968647, https://openalex.org/W3201722188 |
| cited_by_count | 33 |
| counts_by_year[0].year | 2024 |
| counts_by_year[0].cited_by_count | 2 |
| counts_by_year[1].year | 2023 |
| counts_by_year[1].cited_by_count | 5 |
| counts_by_year[2].year | 2022 |
| counts_by_year[2].cited_by_count | 4 |
| counts_by_year[3].year | 2021 |
| counts_by_year[3].cited_by_count | 6 |
| counts_by_year[4].year | 2020 |
| counts_by_year[4].cited_by_count | 6 |
| counts_by_year[5].year | 2019 |
| counts_by_year[5].cited_by_count | 10 |
| locations_count | 4 |
| best_oa_location.id | doi:10.21037/tlcr.2018.06.09 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2764539079 |
| best_oa_location.source.issn | 2218-6751, 2226-4477 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 2218-6751 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Translational Lung Cancer Research |
| best_oa_location.source.host_organization | https://openalex.org/P4310321814 |
| best_oa_location.source.host_organization_name | AME Publishing Company |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310321814 |
| best_oa_location.license | cc-by-nc-nd |
| best_oa_location.pdf_url | https://tlcr.amegroups.com/article/viewFile/22942/17376 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Translational Lung Cancer Research |
| best_oa_location.landing_page_url | https://doi.org/10.21037/tlcr.2018.06.09 |
| primary_location.id | doi:10.21037/tlcr.2018.06.09 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S2764539079 |
| primary_location.source.issn | 2218-6751, 2226-4477 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 2218-6751 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Translational Lung Cancer Research |
| primary_location.source.host_organization | https://openalex.org/P4310321814 |
| primary_location.source.host_organization_name | AME Publishing Company |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310321814 |
| primary_location.license | cc-by-nc-nd |
| primary_location.pdf_url | https://tlcr.amegroups.com/article/viewFile/22942/17376 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Translational Lung Cancer Research |
| primary_location.landing_page_url | https://doi.org/10.21037/tlcr.2018.06.09 |
| publication_date | 2018-11-14 |
| publication_year | 2018 |
| referenced_works | https://openalex.org/W2063264144, https://openalex.org/W2112387900, https://openalex.org/W6639545935, https://openalex.org/W2010121426, https://openalex.org/W1982488143, https://openalex.org/W2198093519, https://openalex.org/W2527905628, https://openalex.org/W2104347254, https://openalex.org/W2156353875, https://openalex.org/W2567564314, https://openalex.org/W2293531514, https://openalex.org/W2557730509, https://openalex.org/W2625684877, https://openalex.org/W2546935275, https://openalex.org/W2181211402, https://openalex.org/W2750913206, https://openalex.org/W2528526203, https://openalex.org/W2683488101, https://openalex.org/W2741036937, https://openalex.org/W2797675588, https://openalex.org/W2738156798, https://openalex.org/W2779221466, https://openalex.org/W6640714399, https://openalex.org/W1804743374, https://openalex.org/W2270930097, https://openalex.org/W2039123767, https://openalex.org/W2222106751, https://openalex.org/W2071793654, https://openalex.org/W1981876938, https://openalex.org/W2256341952, https://openalex.org/W2609289346, https://openalex.org/W4213393773, https://openalex.org/W4245424574, https://openalex.org/W1893566975, https://openalex.org/W4211226325, https://openalex.org/W2560367415, https://openalex.org/W2175480754, https://openalex.org/W2796582438, https://openalex.org/W1940241680, https://openalex.org/W2531671724, https://openalex.org/W2049553585, https://openalex.org/W2572174216, https://openalex.org/W4318262605, https://openalex.org/W2769570103 |
| referenced_works_count | 44 |
| abstract_inverted_index.1 | 48, 85, 187 |
| abstract_inverted_index.a | 65, 134 |
| abstract_inverted_index.It | 79 |
| abstract_inverted_index.as | 39 |
| abstract_inverted_index.at | 147 |
| abstract_inverted_index.be | 90, 111, 157, 197 |
| abstract_inverted_index.by | 31, 96 |
| abstract_inverted_index.in | 55, 77, 92, 138, 170 |
| abstract_inverted_index.is | 20, 52, 80 |
| abstract_inverted_index.it | 19 |
| abstract_inverted_index.of | 2, 11, 64, 162, 207 |
| abstract_inverted_index.to | 27, 75, 107, 110, 136, 158, 198 |
| abstract_inverted_index.CD8 | 128 |
| abstract_inverted_index.DNA | 122 |
| abstract_inverted_index.ROS | 185 |
| abstract_inverted_index.The | 0 |
| abstract_inverted_index.and | 14, 70, 117, 127, 194, 212 |
| abstract_inverted_index.are | 25, 73, 144 |
| abstract_inverted_index.but | 101 |
| abstract_inverted_index.for | 4, 192 |
| abstract_inverted_index.may | 131 |
| abstract_inverted_index.not | 145 |
| abstract_inverted_index.now | 53 |
| abstract_inverted_index.set | 206 |
| abstract_inverted_index.the | 9, 33, 59, 62, 93, 151, 165, 190, 204 |
| abstract_inverted_index.able | 26 |
| abstract_inverted_index.all, | 150 |
| abstract_inverted_index.also | 132 |
| abstract_inverted_index.been | 37 |
| abstract_inverted_index.cell | 45 |
| abstract_inverted_index.from | 209 |
| abstract_inverted_index.have | 36, 133 |
| abstract_inverted_index.lack | 10 |
| abstract_inverted_index.main | 152 |
| abstract_inverted_index.near | 94 |
| abstract_inverted_index.play | 137 |
| abstract_inverted_index.role | 135 |
| abstract_inverted_index.that | 22, 82 |
| abstract_inverted_index.this | 102, 160 |
| abstract_inverted_index.will | 89, 103, 156, 196, 202 |
| abstract_inverted_index.(ALK) | 183 |
| abstract_inverted_index.(MMR) | 125 |
| abstract_inverted_index.Above | 149 |
| abstract_inverted_index.While | 121 |
| abstract_inverted_index.allow | 108 |
| abstract_inverted_index.assay | 67 |
| abstract_inverted_index.death | 46 |
| abstract_inverted_index.given | 8 |
| abstract_inverted_index.novel | 105 |
| abstract_inverted_index.roles | 143 |
| abstract_inverted_index.small | 114 |
| abstract_inverted_index.tests | 34, 163, 211 |
| abstract_inverted_index.their | 142 |
| abstract_inverted_index.these | 210 |
| abstract_inverted_index.using | 113 |
| abstract_inverted_index.which | 35, 201 |
| abstract_inverted_index.(EGFR) | 178 |
| abstract_inverted_index.(PD-1) | 49 |
| abstract_inverted_index.(ROS1) | 188 |
| abstract_inverted_index.(TMB), | 100 |
| abstract_inverted_index.T-cell | 129 |
| abstract_inverted_index.[e.g., | 173 |
| abstract_inverted_index.burden | 99 |
| abstract_inverted_index.change | 76 |
| abstract_inverted_index.facing | 154 |
| abstract_inverted_index.factor | 176 |
| abstract_inverted_index.fulfil | 28 |
| abstract_inverted_index.future | 95 |
| abstract_inverted_index.growth | 175 |
| abstract_inverted_index.highly | 12, 15 |
| abstract_inverted_index.kinase | 182 |
| abstract_inverted_index.likely | 74 |
| abstract_inverted_index.narrow | 119 |
| abstract_inverted_index.repair | 124 |
| abstract_inverted_index.tissue | 115 |
| abstract_inverted_index.tumour | 97 |
| abstract_inverted_index.useful | 41 |
| abstract_inverted_index.within | 118 |
| abstract_inverted_index.(PD-L1) | 86 |
| abstract_inverted_index.already | 168 |
| abstract_inverted_index.complex | 205 |
| abstract_inverted_index.density | 130 |
| abstract_inverted_index.develop | 199 |
| abstract_inverted_index.future. | 78 |
| abstract_inverted_index.markers | 167 |
| abstract_inverted_index.perform | 159 |
| abstract_inverted_index.protein | 47 |
| abstract_inverted_index.provide | 213 |
| abstract_inverted_index.remains | 6, 68 |
| abstract_inverted_index.require | 104 |
| abstract_inverted_index.results | 208 |
| abstract_inverted_index.routine | 56 |
| abstract_inverted_index.samples | 116 |
| abstract_inverted_index.testing | 23, 71, 109, 126 |
| abstract_inverted_index.although | 58 |
| abstract_inverted_index.clinical | 171 |
| abstract_inverted_index.complex, | 69 |
| abstract_inverted_index.criteria | 30 |
| abstract_inverted_index.lymphoma | 181 |
| abstract_inverted_index.mismatch | 123 |
| abstract_inverted_index.mutation | 98 |
| abstract_inverted_index.patients | 3 |
| abstract_inverted_index.practice | 172 |
| abstract_inverted_index.present. | 148 |
| abstract_inverted_index.probable | 81 |
| abstract_inverted_index.receptor | 177 |
| abstract_inverted_index.specific | 13 |
| abstract_inverted_index.alongside | 164 |
| abstract_inverted_index.challenge | 153, 191 |
| abstract_inverted_index.completed | 112 |
| abstract_inverted_index.epidermal | 174 |
| abstract_inverted_index.essential | 21 |
| abstract_inverted_index.integrate | 203 |
| abstract_inverted_index.licencing | 29 |
| abstract_inverted_index.molecular | 166 |
| abstract_inverted_index.multitude | 161 |
| abstract_inverted_index.mutation, | 179 |
| abstract_inverted_index.practice, | 57 |
| abstract_inverted_index.protocols | 72 |
| abstract_inverted_index.providing | 32, 40 |
| abstract_inverted_index.regarding | 61 |
| abstract_inverted_index.regimens. | 216 |
| abstract_inverted_index.response, | 141 |
| abstract_inverted_index.selection | 1, 63 |
| abstract_inverted_index.sensitive | 16 |
| abstract_inverted_index.situation | 60 |
| abstract_inverted_index.solutions | 106 |
| abstract_inverted_index.validated | 38 |
| abstract_inverted_index.Programmed | 44 |
| abstract_inverted_index.algorithms | 200 |
| abstract_inverted_index.anaplastic | 180 |
| abstract_inverted_index.assessment | 51, 88 |
| abstract_inverted_index.clinicians | 195 |
| abstract_inverted_index.expression | 50, 87 |
| abstract_inverted_index.management | 215 |
| abstract_inverted_index.particular | 66 |
| abstract_inverted_index.predicting | 139 |
| abstract_inverted_index.predictive | 42 |
| abstract_inverted_index.programmed | 83 |
| abstract_inverted_index.biomarkers. | 17 |
| abstract_inverted_index.challenging | 7 |
| abstract_inverted_index.established | 54, 169 |
| abstract_inverted_index.timeframes. | 120 |
| abstract_inverted_index.death-ligand | 84 |
| abstract_inverted_index.information. | 43 |
| abstract_inverted_index.laboratories | 24, 155 |
| abstract_inverted_index.pathologists | 193 |
| abstract_inverted_index.supplemented | 91 |
| abstract_inverted_index.well-defined | 146 |
| abstract_inverted_index.Nevertheless, | 18 |
| abstract_inverted_index.immunotherapy | 5, 140 |
| abstract_inverted_index.proto-oncogene | 186 |
| abstract_inverted_index.translocation, | 184 |
| abstract_inverted_index.translocation]; | 189 |
| abstract_inverted_index.clinically-useful | 214 |
| cited_by_percentile_year.max | 99 |
| cited_by_percentile_year.min | 94 |
| corresponding_author_ids | https://openalex.org/A5061777679 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 4 |
| corresponding_institution_ids | https://openalex.org/I2799307867 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8600000143051147 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.90324724 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |